<DOC>
	<DOCNO>NCT02439970</DOCNO>
	<brief_summary>To compare efficacy brincidofovir ( BCV ) valganciclovir ( vGCV ) prevention cytomegalovirus ( CMV ) disease kidney transplant allograft recipient CMV seronegative pretransplant receive kidney CMV seropositive donor</brief_summary>
	<brief_title>SUSTAIN : A Randomized , Double-Blind , Multicenter , Phase 3 Study Efficacy , Safety , Tolerability Brincidofovir Versus Valganciclovir Prevention Cytomegalovirus Disease CMV Seronegative Kidney Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>CMV seronegative recipient receive kidney CMV seropositive donor First second kidney transplant recipient Within 14 day post transplant , eGFR &gt; 10 mL/min CG equation Able ingest tablet Multiorgan transplant recipient Plasma CMV PCR &gt; LOD central lab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>kidney transplant allograft</keyword>
	<keyword>recipient</keyword>
</DOC>